Lind Kevin Robert 4

What Happened

• Kevin Robert Lind, a director of Avalo Therapeutics, was granted a derivative award covering 20,100 shares on 2026-06-02. The Form 4 reports an acquisition price of $0.00 and a total reported value of $0 (derivative award). This was an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-02; Filing date: 2026-06-04 (timely).
• Instrument: Derivative award reported as 20,100 shares at $0.00 per share (Form 4 shows $0 value).
• Vesting: Footnote — the stock option vests 100% on the first anniversary of the grant date, subject to continued service.
• Shares owned after transaction: not provided in the summary you supplied.
• Filing status: Not marked late (no L code reported).

Context

• This was an equity award (stock option) grant, not a sale. The award vests in one year; there is no indication the shares were exercised or sold immediately. Such grants are commonly part of director compensation and do not by themselves indicate a buy/sell signal.